TEST:

Stockholm3

No abstract available

P=N/A; In regions where access to MRI is lacking, the Stockholm3 test can aid in selecting patients for systematic prostate biopsy. ClinicalTrials.gov Identifier: NCT03377881.

"The annual 2024 European Association of Urology (EAU) meeting was held in Paris from April 5 – 8. More sophisticated risk adapted prostate cancer strategies was a focus area, including six abstracts evaluating Stockholm3 in populations across Europe and North America. An abstract utilizing a baseline Stockholm3 score to predict biochemical recurrence after prostatectomy was awarded best abstract in the prostate cancer biopsy indication session."

This review found that a combination of approaches, centred on the use of pre-biopsy MRI, may improve the detection of clinically significant cancers and reduce (i) the diagnosis of clinically insignificant cancers and (ii) unnecessary biopsies, compared with PSA testing and standard biopsy alone. However, the impact of such interventions on longer term outcomes such as prostate cancer-specific mortality has not yet been assessed.

P=N/A; Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024

"In 2002, Region Stockholm and Region Gotland (the Region) began a joint three-year project by offering organised prostate cancer testing (OPT) to all 50-year-old men living in the Region. In 2024, an evaluation of the Stockholm3 test will be made in a research project at Karolinska Institutet in collaboration with OPT."

This study underscores the effectiveness of the protocol-driven diagnostic process at Capio PCC, enabling earlier detection of intermediate-risk prostate cancer and reducing the need for MRI assessments compared with standard prostate cancer care in Sweden. At the Capio Prostate Cancer Center, a novel diagnostic approach incorporating prostate-specific antigen, Stockholm3, magnetic resonance imaging, and targeted biopsies has been implemented to enhance prostate cancer testing and diagnosis in Stockholm, Sweden.

"In the latest edition of European Urology Open Sciences, the Prostate Cancer Center at Capio St. Göran’s Hospital is highlighted for its well-invested and structured model for prostate cancer diagnostics. This model, based on Stockholm3 combined with MRI and targeted biopsies has been shown to significantly improve the diagnostic outcome and health economics."

No abstract available

"The primary results of the landmark SEPTA trial, with over 2,000 racially and ethnically diverse biopsied men recruited in the US and Canada, were presented...at the ASCO-GU (The American Society of Clinical Oncology – Genitourinary Cancer Symposium) conference in San Francisco on January 26. The study found that use of the blood-based biomarker Stockholm3 was more accurate and could avoid up to half of unnecessary biopsies compared to current clinical practice. The findings were similar across all racial and ethnic groups."

No abstracts available

No abstracts available

No abstracts available

The study demonstrates that the protocol-driven and diagnostic process at Capio PCC leads to an effective care, enabling earlier diagnosis of intermediate risk cancer and reducing the number of MRIs as well as incidence of overdiagnosis of low-risk cancers compared to the prostate cancer care in Sweden.

In an ethnically diverse population, Stockholm3 would significantly reduce unnecessary prostate biopsies and diagnosis of ISUP 1 cancer at a similar sensitivity of PSA for detecting clinically significant cancer. Clinical trial information: NCT04583072.

P=N/A; Recruiting --> Completed | Trial completion date: Oct 2022 --> Oct 2023

Our results show favorable clinical outcomes for the blood-based Stockholm3 biomarker test in a Central European patient cohort.

Systematic biopsies can be omitted in patients with a positive Stockholm3 test and a negative MRI when there is a volume cutoff in the test report. With no volume cutoff, biopsies can be considered with shared decision-making.

No abstract available

P=N/A, N=400, Recruiting, Karolinska Institutet | Trial primary completion date: Sep 2023 --> Dec 2023

No abstract available

"A3P Biomedical AB...and BioAgilytix, a global bioanalytical services provider, have entered a partnership with the aim of introducing Stockholm3, as a Lab Developed Test (LDT) designed to redefine the standard of care for early detection of prostate cancer in the USA."